Exane Derivatives’s Carvana CVNA Stock Holding History

Exane Derivatives’s Portfolio CVNA Stock Details CVNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-5,840	Closed	-$139K	–	833
2022 Q1	$139K	Buy	5,840 +620	+12%	+$18.1K	0.04%	418
2021 Q4	$242K	Sell	5,220 -4,355	-45%	-$240K	0.06%	302
2021 Q3	$577K	Sell	9,575 -1,230	-11%	-$81.8K	0.14%	159
2021 Q2	$698K	Buy	+10,805	New	+$588K	0.16%	127

Other funds holding CVNA

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CIP

CAS Investment Partners Westport, Connecticut $1.88B AUM 2.5% 1-Year Est. Return

SHIM

Spruce House Investment Management New York $3.4B AUM 30.65% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Exane Derivatives's CVNA Position: Q2 2022 in Review

Exane Derivatives sold out of Carvana (CVNA) in Q2 2022, closing a stake of 5,840 shares — an estimated $139K sold.

Exane Derivatives first reported a position in CVNA in Q2 2021 and held it in 4 quarters. The position peaked at $698K in Q2 2021. 307 funds tracked by Wall St. Rank hold CVNA as of Q2 2022.

Exane Derivatives reported no remaining Carvana position as of Q2 2022 after selling out during the quarter.
Exane Derivatives sold 5,840 Carvana shares in Q2 2022, an estimated $139K.
Exane Derivatives first reported a position in Carvana in Q2 2021 and held it in 4 quarters.
Exane Derivatives's Carvana position peaked at $698K in Q2 2021.
307 funds tracked by Wall St. Rank held Carvana as of Q2 2022.

Based on Exane Derivatives's 13F filing for Q2 2022, filed 12 Jul 2022.